Alexander V. Grigoriev
Alexander V. Grigoriev has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Sidorova
OOO CSU "Analytical Spectrometry
3 shared publications - A. V. Kapashin
Valenta Pharm JSC
3 shared publications - Aleksander A. Globenko
Valenta Pharm JSC
3 shared publications - Maksim A. Pasko
Valenta Pharm JSC
3 shared publications - A. I. Bashkatova
Valenta Pharm JSC
2 shared publications - A. S. Goncharov
Serta Clinic LLC
2 shared publications
Latest Publications
- Open Access
- 25 August 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (7) , 6416
Bioequivalence study of Rosuvastatin in healthy volunteers after a single dose on an empty stomach
Aim. To assess comparative pharmacokinetics and establish bioequivalence of film-coated Rosuvastatin 20 mg (OOO NTFF "POLYSAN", Russia) (T) and film-coated Crestor® 20 mg (AstraZeneca UK Limited, UK) (R) after a single dose of 20 mg on an empty stomach in healthy volunteers, as well as to study their safety and tolerability.Material and methods. This open-label, randomized, crossover, two-period study of comparative pharmacokinetics and bioequivalence of T and R following a single dose in the fasted state was conducted in 46 healthy volunteers at a single center. After randomization, volunteers in each Study Period received a single 20 mg rosuvastatin dose in a different sequence (TR or RT). Periods I and II were separated by a 14-day washout period. Plasma rosuvastatin concentrations were determined by high-liquid chromatography–mass spectrometry. Following pharmacokinetic parameters were calculated: area under the concentration-time from 0 to 72 h (AUC0-t) and the maximum concentration (Cmax). The drugs were considered bioequivalent if the 90% confidence intervals (CI) of the T/R geometric mean ratios for Cmax and AUC0-t were in the range of 80-125%. Safety assessment included analysis of vital signs, physical examination, laboratory tests, 12-lead electrocardiography (ECG), and registration of adverse events (AEs) during the study.Results. Of the 46 randomized volunteers, 44 comprised the safety population. Forty two participants completed the study without significant protocol deviations and comprised the population for pharmacokinetic, statistical analysis and bioequivalence. The values of pharmacokinetic parameters T and R were comparable. The 90% CIs for Cmax and AUC0-t were within the acceptable bioequivalence range of 80,00-125,00% as follows: 91,71-107,41% and 91,58-115,83%, respectively. A total of 2 AEs were recorded in 1 participant after receiving the reference drug. The frequency of AEs did not differ between the groups. No clinically significant deviations in vital signs, physical examinations, laboratory tests, or ECG data were observed in either group during the study.Conclusion. T and R were considered bioequivalent and demonstrated similar safety profiles.
- 25 August 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (7) , 6416
Open AccessBioequivalence study of Rosuvastatin in healthy volunteers after a single dose on an empty stomach
Aim. To assess comparative pharmacokinetics and establish bioequivalence of film-coated Rosuvastatin 20 mg (OOO NTFF "POLYSAN", Russia) (T) and film-coated Crestor® 20 mg (AstraZeneca UK Limited, UK) (R) after a single dose of 20 mg on an empty stomach in healthy volunteers, as well as to study their safety and tolerability.Material and methods. This open-label, randomized, crossover, two-period study of comparative pharmacokinetics and bioequivalence of T and R following a single dose in the fasted state was conducted in 46 healthy volunteers at a single center. After randomization, volunteers in each Study Period received a single 20 mg rosuvastatin dose in a different sequence (TR or RT). Periods I and II were separated by a 14-day washout period. Plasma rosuvastatin concentrations were determined by high-liquid chromatography–mass spectrometry. Following pharmacokinetic parameters were calculated: area under the concentration-time from 0 to 72 h (AUC0-t) and the maximum concentration (Cmax). The drugs were considered bioequivalent if the 90% confidence intervals (CI) of the T/R geometric mean ratios for Cmax and AUC0-t were in the range of 80-125%. Safety assessment included analysis of vital signs, physical examination, laboratory tests, 12-lead electrocardiography (ECG), and registration of adverse events (AEs) during the study.Results. Of the 46 randomized volunteers, 44 comprised the safety population. Forty two participants completed the study without significant protocol deviations and comprised the population for pharmacokinetic, statistical analysis and bioequivalence. The values of pharmacokinetic parameters T and R were comparable. The 90% CIs for Cmax and AUC0-t were within the acceptable bioequivalence range of 80,00-125,00% as follows: 91,71-107,41% and 91,58-115,83%, respectively. A total of 2 AEs were recorded in 1 participant after receiving the reference drug. The frequency of AEs did not differ between the groups. No clinically significant deviations in vital signs, physical examinations, laboratory tests, or ECG data were observed in either group during the study.Conclusion. T and R were considered bioequivalent and demonstrated similar safety profiles.
- Open Access
- 22 January 2024
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 32-40
Study of antacid effect of the drug Antareit® in healthy volunteers
The aim. Study of pharmacodynamic parameters and confirmation of pharmacodynamic equivalence (bioequivalence) of the drugs Antareit® (INN: magaldrate), chewable tablets, 800 mg (Valenta Pharm JSC, Russia) and Riopan (INN magaldrate), chewable tablets, 800 mg (Takeda GmbH, Germany). Material and methods. An open randomized crossover study was conducted to investigate the pharmacodynamics of the study drug Antareit® and the reference drug Riopan, assessing their bioequivalence after taking 2 chewable tablets of the study or reference drug 3 times a day. The study involved 40 healthy volunteers who were randomized into 2 groups of 20 people depending on the sequence of drug administration in study periods I and II. Intragastric acidity was measured with a pH-probe within 30 minutes before and for one hour after taking the study drugs. Based on the data obtained, 90% confidence intervals (CI) were calculated for the pharmacodynamic parameter AUCABL, reflecting the area above the baseline pH. The safety of the study drugs was assessed by the frequency and severity of adverse events (AEs). Results. Statistical analysis showed that the 90% CI for the ratio of the mean values of the AUC ABL parameter of the study drug to the reference drug did not fall below 80% (90% CI: 80.55–119.49). During the study, 18 adverse events (AEs) were reported in 15.4% (6 of 39) of volunteers in the safety population, and there were no statistically significant differences in the incidence of AEs between groups, nor in the incidence of AEs depending on the drug taken. Conclusion. The studied drugs are pharmacodynamically equivalent and have a similar safety profile when administered repeatedly.
- 22 January 2024
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 32-40
Open AccessStudy of antacid effect of the drug Antareit® in healthy volunteers
The aim. Study of pharmacodynamic parameters and confirmation of pharmacodynamic equivalence (bioequivalence) of the drugs Antareit® (INN: magaldrate), chewable tablets, 800 mg (Valenta Pharm JSC, Russia) and Riopan (INN magaldrate), chewable tablets, 800 mg (Takeda GmbH, Germany). Material and methods. An open randomized crossover study was conducted to investigate the pharmacodynamics of the study drug Antareit® and the reference drug Riopan, assessing their bioequivalence after taking 2 chewable tablets of the study or reference drug 3 times a day. The study involved 40 healthy volunteers who were randomized into 2 groups of 20 people depending on the sequence of drug administration in study periods I and II. Intragastric acidity was measured with a pH-probe within 30 minutes before and for one hour after taking the study drugs. Based on the data obtained, 90% confidence intervals (CI) were calculated for the pharmacodynamic parameter AUCABL, reflecting the area above the baseline pH. The safety of the study drugs was assessed by the frequency and severity of adverse events (AEs). Results. Statistical analysis showed that the 90% CI for the ratio of the mean values of the AUC ABL parameter of the study drug to the reference drug did not fall below 80% (90% CI: 80.55–119.49). During the study, 18 adverse events (AEs) were reported in 15.4% (6 of 39) of volunteers in the safety population, and there were no statistically significant differences in the incidence of AEs between groups, nor in the incidence of AEs depending on the drug taken. Conclusion. The studied drugs are pharmacodynamically equivalent and have a similar safety profile when administered repeatedly.
- Open Access
- 3 November 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 94-103
Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study
Aim. The primary aim of this study was to evaluate the pharmacokinetic parameters and confirm the bioequivalence of drugs containing gidazepam, namely Gidazepam® (Valenta Pharm, Russia) and Gidazepam VIC (VIVA Pharm, Republic of Kazakhstan), after a single administration of 1 tablet (50 mg) to healthy volunteers under fasting conditions. The secondary aim was a comparative analysis of safety profiles (adverse events) after a single administration of the studied drugs.Materials and methods. An open, randomized, crossover, two-period comparative study of pharmacokinetics and bioequivalence with adaptive design was conducted in healthy volunteers. Blood sampling was performed 15 minutes before and 20 min, 40 min, 1 h, 2 h, 3 h, 3.5 h, 4 h, 4.5 h, 5 h, 6 h, 8 h, 12 h, 24 h, 48 h, and 72 h after drug administration. High-performance liquid chromatography-tandem mass spectrometry was used for the evaluation of gidazepam and its metabolite (desalkylgidazepam) concentration with the subsequent calculation of pharmacokinetic parameters.Results. From both formulations, gidazepam was quickly absorbed and biotransformed into an active metabolite. Studied drugs had similar pharmacokinetic profiles, as 90% confidence intervals for the ratio of geometric means for Cmax and AUC(0-72) were within the bioequivalence acceptance range of 80.00–125.00 %. No adverse events were recorded as a result of clinical, laboratory or instrument evaluations during the study.Conclusion. Study drugs are considered bioequivalent and show comparable tolerability after a single administration under fasting conditions.
- 3 November 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 94-103
Open AccessStudy of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study
Aim. The primary aim of this study was to evaluate the pharmacokinetic parameters and confirm the bioequivalence of drugs containing gidazepam, namely Gidazepam® (Valenta Pharm, Russia) and Gidazepam VIC (VIVA Pharm, Republic of Kazakhstan), after a single administration of 1 tablet (50 mg) to healthy volunteers under fasting conditions. The secondary aim was a comparative analysis of safety profiles (adverse events) after a single administration of the studied drugs.Materials and methods. An open, randomized, crossover, two-period comparative study of pharmacokinetics and bioequivalence with adaptive design was conducted in healthy volunteers. Blood sampling was performed 15 minutes before and 20 min, 40 min, 1 h, 2 h, 3 h, 3.5 h, 4 h, 4.5 h, 5 h, 6 h, 8 h, 12 h, 24 h, 48 h, and 72 h after drug administration. High-performance liquid chromatography-tandem mass spectrometry was used for the evaluation of gidazepam and its metabolite (desalkylgidazepam) concentration with the subsequent calculation of pharmacokinetic parameters.Results. From both formulations, gidazepam was quickly absorbed and biotransformed into an active metabolite. Studied drugs had similar pharmacokinetic profiles, as 90% confidence intervals for the ratio of geometric means for Cmax and AUC(0-72) were within the bioequivalence acceptance range of 80.00–125.00 %. No adverse events were recorded as a result of clinical, laboratory or instrument evaluations during the study.Conclusion. Study drugs are considered bioequivalent and show comparable tolerability after a single administration under fasting conditions.
- Open Access
- 15 August 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (4) , 80-88
Pharmacokinetic parameters, safety and drug-drug interactions of mirtazapine and tizanidine, combined in the new original drug Dorsumio®
Objective: to study the pharmacokinetic parameters and safety of Dorsumio® (mirtazapine + tizanidine, extended-release tablets, 15 mg + 6 mg, JSC Valenta Pharm, Russia) taken once by healthy volunteers in comparison with Calixta®, a monocomponent drug (INN: Mirtazapine, filmcoated tablets, 30 mg, Belupo, Drugs and Cosmetics d.d., Republic of Croatia) and Sirdalud® MR (INN: Tizanidine, modified-release capsules, 6 mg, Novartis Pharma AG, Switzerland) with an evaluation of their drug interactions when taken concomitantly or separately.Material and methods. A two-stage, randomized, comparative cross-over study of the pharmacokinetics and safety of the complex drug Dorsumio® was conducted. In the first stage, volunteers alternated between taking one or two tablets of the study drug in two administration periods; in the second stage, subjects alternated between taking the reference monodrugs Calixta® and Sirdalud® MR alone and in a joint combination in three administration periods. A total of 38 volunteers were randomized into the study, of which 14 subjects participated in the first and 24 in the second stage of the study. Quantitative levels of mirtazapine and tizanidine were determined by high-performance liquid chromatography with tandem mass spectrometry. Based on the data obtained, the main pharmacokinetic parameters reflecting the bioavailability of each drug were calculated, and the mutual influence of their combination on pharmacokinetics was also studied. During the study, vital signs and laboratory parameters of the subjects were monitored, and the occurrence of adverse events (AEs) and serious AEs was recorded.Results. A two-fold increase in the dose of the combination drug Dorsumio® resulted in a comparable increase in the pharmacokinetics of the individual drugs. There was no significant reciprocal effect of mirtazapine and tizanidine on their pharmacokinetic parameters. In one of the subjects participating in the second stage of the study, two mild side effects were registered after the joint use of Calixta® and Sirdalud® MR that did not require medical intervention and resolved on their own without health consequences.Conclusion. There were no differences in the safety profile of the combined use of mirtazapine and tizanidine in the form of a free or fixed combination. It was shown that the investigated drug combination had no mutual influence on the pharmacokinetics of the individual components.
- 15 August 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (4) , 80-88
Open AccessPharmacokinetic parameters, safety and drug-drug interactions of mirtazapine and tizanidine, combined in the new original drug Dorsumio®
Objective: to study the pharmacokinetic parameters and safety of Dorsumio® (mirtazapine + tizanidine, extended-release tablets, 15 mg + 6 mg, JSC Valenta Pharm, Russia) taken once by healthy volunteers in comparison with Calixta®, a monocomponent drug (INN: Mirtazapine, filmcoated tablets, 30 mg, Belupo, Drugs and Cosmetics d.d., Republic of Croatia) and Sirdalud® MR (INN: Tizanidine, modified-release capsules, 6 mg, Novartis Pharma AG, Switzerland) with an evaluation of their drug interactions when taken concomitantly or separately.Material and methods. A two-stage, randomized, comparative cross-over study of the pharmacokinetics and safety of the complex drug Dorsumio® was conducted. In the first stage, volunteers alternated between taking one or two tablets of the study drug in two administration periods; in the second stage, subjects alternated between taking the reference monodrugs Calixta® and Sirdalud® MR alone and in a joint combination in three administration periods. A total of 38 volunteers were randomized into the study, of which 14 subjects participated in the first and 24 in the second stage of the study. Quantitative levels of mirtazapine and tizanidine were determined by high-performance liquid chromatography with tandem mass spectrometry. Based on the data obtained, the main pharmacokinetic parameters reflecting the bioavailability of each drug were calculated, and the mutual influence of their combination on pharmacokinetics was also studied. During the study, vital signs and laboratory parameters of the subjects were monitored, and the occurrence of adverse events (AEs) and serious AEs was recorded.Results. A two-fold increase in the dose of the combination drug Dorsumio® resulted in a comparable increase in the pharmacokinetics of the individual drugs. There was no significant reciprocal effect of mirtazapine and tizanidine on their pharmacokinetic parameters. In one of the subjects participating in the second stage of the study, two mild side effects were registered after the joint use of Calixta® and Sirdalud® MR that did not require medical intervention and resolved on their own without health consequences.Conclusion. There were no differences in the safety profile of the combined use of mirtazapine and tizanidine in the form of a free or fixed combination. It was shown that the investigated drug combination had no mutual influence on the pharmacokinetics of the individual components.
- 1 July 2023
- Published by Springer Nature in Chemical and Petroleum Engineering
- Vol. 59 (3-4) , 335-339
Comprehensive Assessment of Pulsation Phenomena and Dynamic Loads in the Working Elements of a Hydraulic Drive
- 1 July 2023
- Published by Springer Nature in Chemical and Petroleum Engineering
- Vol. 59 (3-4) , 335-339
Comprehensive Assessment of Pulsation Phenomena and Dynamic Loads in the Working Elements of a Hydraulic Drive
- 26 July 2022
- Published by AccScience Publishing in Asian Journal of Water, Environment and Pollution
- Vol. 19 (4) , 41-47
Features of Pesticide-Contaminated Surface Water
This work aims to investigate the concentration indices of 14 pesticides in the major water bodies of the Southern Federal District of the Russian Federation. The study was conducted in 2019 using samples of bottom sediments and surface waters collected from three reservoirs (Krasnodar, Proletarian, and Veselovsky) and two rivers (Don and Sal). Concentrations of active pesticide substances were studied, and the results were benchmarked against 2018. In 2019, 14 active pesticide substances were detected in water and sediment samples from the three reservoirs under study. Maximum pesticide concentrations were observed in the spring of 2019 and autumn 2018. Total concentration indices in these time frames were similar, but autumn 2019 is 20 times lower than 2018 (0.7 versus 6.5, p ≤ 0.001). Total pesticide concentrations for rivers and reservoirs averaged about the same (0.15-0.80, p ≥ 0.05). There are different levels of pesticides in rivers and reservoirs. The detected pesticide concentrations did not exceed the maximum allowable concentrations, but the cumulative effect can have a harmful impact on hydrobionts in the future.
- 26 July 2022
- Published by AccScience Publishing in Asian Journal of Water, Environment and Pollution
- Vol. 19 (4) , 41-47
Features of Pesticide-Contaminated Surface Water
This work aims to investigate the concentration indices of 14 pesticides in the major water bodies of the Southern Federal District of the Russian Federation. The study was conducted in 2019 using samples of bottom sediments and surface waters collected from three reservoirs (Krasnodar, Proletarian, and Veselovsky) and two rivers (Don and Sal). Concentrations of active pesticide substances were studied, and the results were benchmarked against 2018. In 2019, 14 active pesticide substances were detected in water and sediment samples from the three reservoirs under study. Maximum pesticide concentrations were observed in the spring of 2019 and autumn 2018. Total concentration indices in these time frames were similar, but autumn 2019 is 20 times lower than 2018 (0.7 versus 6.5, p ≤ 0.001). Total pesticide concentrations for rivers and reservoirs averaged about the same (0.15-0.80, p ≥ 0.05). There are different levels of pesticides in rivers and reservoirs. The detected pesticide concentrations did not exceed the maximum allowable concentrations, but the cumulative effect can have a harmful impact on hydrobionts in the future.
- Open Access
- 19 December 2021
- Published by T.F. Gorbachev Kuzbass State Technicak University in Mining equipment and electromechanics
- No. 5,p. 41-50
AUTOMATION OF VERIFICATION AND CALIBRATION OF ELECTRICAL MEASURING INSTRUMENTS
Автоматизация операций поверки и калибровки электроизмерительных приборов
- 19 December 2021
- Published by T.F. Gorbachev Kuzbass State Technicak University in Mining equipment and electromechanics
- No. 5,p. 41-50
Open AccessAUTOMATION OF VERIFICATION AND CALIBRATION OF ELECTRICAL MEASURING INSTRUMENTS
Автоматизация операций поверки и калибровки электроизмерительных приборов
- Open Access
- 1 September 2021
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 852 (1) , 012105
Influence of Azotovite and Phosphatovite on the Productivity of Oats and the Fertility of Sod-Podzolic Soil in the Conditions of the Novgorod Region
Sod-podzolic low-fertile soils (70% of the territory) are mainly widespread in the Novgorod region. According to the granulometric composition, the sown areas are mainly light and medium loamy. Technological operations include two methods of application of microbial fertilizers Azotovit and Phosphatovit: pre-sowing seed treatment (A+Ph, 2 l/t of each preparation) + foliar treatment in the phase of entering the tube (A+Ph, 1 l/ha of each preparation) together with mineral fertilizers (based on the planned yield and reduced by 50%), which contributes to an increase in oat grain production by 32 and 33%, and digestible protein by 30 and 34%, respectively, in relation to background 1 and background 2, where microbial fertilizers were not used. As an organic fertilizer, chopped straw of spring barley was plowed (4 t/ha) with addition of 10 kg of nitrogen for each ton. After harvesting cereals, a disc harrow was used to chop the straw and mix it with the soil at a depth of 0-10 cm.Taking into account the main articles of the arrival of humus (stubble-root residues of cereals and straw) in all variants of the experiment, soil fertility increased and its energy potential increased from 9 up to 16 GJ/ha.
- 1 September 2021
- Published by IOP Publishing in IOP Conference Series: Earth and Environmental Science
- Vol. 852 (1) , 012105
Open AccessInfluence of Azotovite and Phosphatovite on the Productivity of Oats and the Fertility of Sod-Podzolic Soil in the Conditions of the Novgorod Region
Sod-podzolic low-fertile soils (70% of the territory) are mainly widespread in the Novgorod region. According to the granulometric composition, the sown areas are mainly light and medium loamy. Technological operations include two methods of application of microbial fertilizers Azotovit and Phosphatovit: pre-sowing seed treatment (A+Ph, 2 l/t of each preparation) + foliar treatment in the phase of entering the tube (A+Ph, 1 l/ha of each preparation) together with mineral fertilizers (based on the planned yield and reduced by 50%), which contributes to an increase in oat grain production by 32 and 33%, and digestible protein by 30 and 34%, respectively, in relation to background 1 and background 2, where microbial fertilizers were not used. As an organic fertilizer, chopped straw of spring barley was plowed (4 t/ha) with addition of 10 kg of nitrogen for each ton. After harvesting cereals, a disc harrow was used to chop the straw and mix it with the soil at a depth of 0-10 cm.Taking into account the main articles of the arrival of humus (stubble-root residues of cereals and straw) in all variants of the experiment, soil fertility increased and its energy potential increased from 9 up to 16 GJ/ha.